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Background: Fusion proteins have unique oncogenic properties and their identification can be useful either as
diagnostic or therapeutic targets. Next generation sequencing data have previously shown a fusion gene formed
between Rad51C and ATXN7 genes in the MCF7 breast cancer cell line. However, the existence of this fusion gene
in colorectal patient tumor tissues is largely still unknown.
Methods: We evaluated for the presence of Rad51C-ATXN7 fusion gene in colorectal tumors and cells by RT-PCR,
PCR, Topo TA cloning, Real time PCR, immunoprecipitation and immunoblotting techniques.
Results: We identified two forms of fusion mRNAs between Rad51C and ATXN7 in the colorectal tumors, including
a Variant 1 (fusion transcript between Rad51C exons 1–7 and ATXN7 exons 6–13), and a Variant 2 (between Rad51C
exons 1–6 and ATXN7 exons 6–13). In silico analysis showed that the Variant 1 produces a truncated protein,
whereas the Variant 2 was predicted to produce a fusion protein with molecular weight of 110 KDa.
Immunoprecipitation and Western blot analysis further showed a 110 KDa protein in colorectal tumors.
5-Azacytidine treatment of LS-174 T cells caused a 3.51-fold increase in expression of the fusion gene (Variant 2) as
compared to no treatment controls evaluated by real time PCR.
Conclusion: In conclusion we found a fusion gene between DNA repair gene Rad51C and neuro-cerebral ataxia
Ataxin-7 gene in colorectal tumors. The in-frame fusion transcript of Variant 2 results in a fusion protein with
molecular weight of 110 KDa. In addition, we found that expression of fusion gene is associated with functional
impairment of Fanconi Anemia (FA) DNA repair pathway in colorectal tumors. The expression of Rad51C-ATXN7 in
tumors warrants further investigation, as it suggests the potential of the fusion gene in treatment and predictive
value in colorectal cancers.
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The cancer genome is characterized by mutations, dele-
tions, amplification, chromosomal translocations and
microsatellite instability. Genomic rearrangements includ-
ing inversions, translocations or interstitial deletions have
also been identified in malignancies. Notable examples are
TMPRSS2-ERG in prostate cancer, and EML4-ALK fusion
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(http://creativecommons.org/publicdomain/zeFusion proteins have unique oncogenic properties and
their identification can be useful either as diagnostic or
therapeutic targets. Examples include the HHLA1-OC90
fusion transcript which is present only in teratocarcin-
oma cell lines [4] and the Kua-UBE2V1 fusion protein
which localized to cytoplasm while UBE2V1 is a nuclear
protein [5]. At the molecular level some fusion genes are
formed by DNA alterations as seen with ALK-C2orf44
fusion in colorectal cancers [6]. Of therapeutic value is
that inhibition of one of the genes could in some cases
be enough to affect the overall activity of the fusion
gene, as has been observed with oncogenic KIF5B-RET,is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
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to multi-kinase inhibitors which inhibit RET [7–9].
Studies using end sequence profiling and massive par-
allel sequencing in MCF-7 breast cancer cell lines have
led to the discovery of a new fusion gene: Rad51C-
ATXN7 [10]. The fusion transcript is formed between
Rad51C exon (1–7) and ATXN7 (6–13). Rad51C gene
resides on chromosome 17q23 and is frequently ampli-
fied in breast tumors, whereas ATXN7 is located on
chromosome 3p21 [10].
Rad51C is involved in both early and late stages of
homologous recombination repair, as a strand transfer
protein. Rad51C and XRCC3 (CX3), and Rad51C and B
(BCDX2) complexes have been shown to participate in
resolution of holiday junction intermediates, but at dif-
ferent stages of HR [11–13]. In vitro biochemical evi-
dence shows that the Rad51C protein forms a dimer by
interaction with Rad51B, which exerts single stranded
DNA-dependent ATPase activity [14, 15].
Moreover, defects in Rad51C have been documented
as the cause of Fanconi Anemia (FA) complementation
group O (FANCO) disorder [16] in which homologous
recombination DNA repair in response to genotoxic in-
sults is disrupted. Genetic and cell biological data have
shown that Rad51C gene has a functional downstream
role in interstrand cross links (ICL’s) during DNA repair
process [16, 17]. Rad51C is shown to participate in ICL
and double strand break-induced DNA damage signal-
ling and controls intra-S-phase checkpoint through
CHK2 activation [17].
The Ataxin7 (ATXN7) is one of autosomal dominant
cerebellar ataxia (ADCA) which is a heterogeneous
group of neurodegenerative disorders characterized by
progressive degeneration of the cerebellum, brain stem
and spinal cord. ADCA is caused by the expansion of
the CAG repeats, producing an elongated polyglutamine
tract in the corresponding protein [18]. The expanded
repeats are variable in size and unstable, usually increas-
ing in size when transmitted to successive generations
[19]. This locus has been mapped to chromosome 3, and
it has been determined that the diseased allele associated
with spinocerebellar ataxia-7 contains 38–130 CAG re-
peats (near the N-terminus), compared to 7–17 in the
normal allele [20]. The encoded protein is a component
of the SPT3/TAF9/GCN5 acetyltransferase (STAGA)
and TBP-free TAF-containing (TFTC) chromatin re-
modelling complexes, and it thus plays a role in tran-
scriptional regulation [21].
The detection of the Rad51C and ATXN7 fusion gene
in the MCF-7 breast cancer cell line is intriguing. How-
ever, the presence of this fusion gene in other tumor
types, or in patients’ tumor specimens has not been pre-
viously documented. Here we report expression of the
novel fusion gene between Rad51C and ATXN7 inhuman colorectal tumors, as well as association of the
fusion gene with functional impairment of the FA DNA
repair pathway.
Results
Identification of the fusion gene Rad51C-ATXN7 in
colorectal tumors
To identify the fusion gene in colorectal tumors, Rad51C
exons 1–7 (accession number NM_058216) and exons
6–13 of ATXN7 (accession number NM_000333) mRNA
sequences were joined. According to the sequence, RT-
PCR specific primers were designed with forward primer
spanning exon-5 of Rad51C and reverse primer located
in exon-8 of ATXN7. Total RNA was isolated from colo-
rectal tumors and non-tumors following the protocol
from TRIzol as mentioned in materials and methods.
The cDNA containing exons 5–7 of Rad51C and exons
6-8 of ATXN7 was amplified by one step RT-PCR using
primers (LF-F and LF-R; Additional file 1: Table S1) that
produced either two amplicons with size of 376 bp, and
316 bp as shown in Fig. 1a, or one product with size of
376 bp (Fig. 1b). The RT-PCR products were gel purified
and subjected to sequencing using the primers (LF-F
and LF-R). Sequencing analysis showed that the 376 bp
product, which we named Variant 1 of the fusion gene,
contained Rad51C (exon 5–7) and ATXN7 (exon- 6–8)
(Fig. 1c). The 316 bp fragment, named Variant 2, con-
tained exons 5–6 of Rad51C and exons 6–8 of ATXN7
(Fig. 1d). In silico analysis showed that the Variant 1 ex-
tends for only three amino acids (aa) after the fusion
junction, and results in a truncated protein and the
Variant 2 forms an inframe fusion transcript with pre-
dicted molecular weight of protein 110 KDa (Additional
file 2: Table S2). Therefore, we used the term of fusion
gene to represent the Variant 2 which produces a fusion
protein in the subsequent text. The structure of the gene
was depicted in Fig. 2.
Frequency of Rad51C-ATXN7 fusion gene in colorectal
tumors
To identify the Rad51C-ATXN7 fusion gene in colorec-
tal tumors, RNA was isolated from 67 tumors following
TRIzol protocol. To amplify the fusion mRNA, we de-
signed Variant specific primers according to the junction
sequences between Rad51C and ATXN7 obtained
previously. The primers (SJF and SJR) were listed in the
Additional file 1: Table S1. Using the fusion specific RT-
PCR (Fig. 3), we analysed 67 tumor samples. Of the 67
tumor RNA samples, 24 (36 %) of tumors showed the
fusion mRNA (Table 1). Overall, the fusion RNA is
expressed mainly in tumors (Fig. 3, Additional file 3:
Table S3). We found six of the 24 tumours expressed
both variants. In addition, we Topo®TA cloned 45 RT-
PCR products amplified using primers LF-F and LF-R,
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Rad51C exon6 ATXN7 exon6
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Fig. 1 RT-PCR amplification and sequencing analysis of fusion gene Rad51C-ATXN7. Colorectal tumor (T) RNA isolated by TRIzol method, was
RT-PCR amplified and sequenced. The primers (Additional file 1: Table S1) that span exon-5 of Rad51C and exon -8 of ATXN7 produced two
fragments of approximately 376 bp and 316 bp (a). The RT-PCR amplified product from a colorectal tumor (T) showed 376 bp fragment only
which was absent in the corresponding non-tumor (NT) sample (b). The RT-PCR amplified products were Topo TA cloned and sequenced. The
RT-PCR products contained a Variant 1 of Rad51C (exon 1–7) and ATXN7 (exon 6–13) fusion gene (c) and a Variant 2 without exon-7 Rad51C
(exon 1–6) ATXN7 (exon 6–13) (d). The solid bar line indicates the sequence breakpoint joining Rad51C and ATXN7
Rad51C
BRC interacting  domain
ATP-binding site















Fig. 2 Schematic representation of portion of the fusion Variant 2 of Rad51C-ATXN7. The fusion transcript and their breakpoints are indicated with
exons of Rad51C and ATXN7. The Variant 2 of the fusion gene transcript is joined at 3′-end of exon-6 of Rad51C with 5′-end of the exon-6 of
ATXN7. The Fusion protein has lost its nuclear localization signal located at the C-terminus end of Rad51C and CAG (Poly glutamine tract) repeat
sequence of ATXN7. The ATP binding site and BRC (BRCA1) interacting domains of Rad51C are conserved at N-terminus of the fusion protein and
SCA7 (Spino- cerebral ataxia 7) domain of ATXN7 conserved at middle terminus of the fusion protein
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Fig. 3 Identification and expression of the fusion gene Variant 2
Rad51C-ATXN7 by RT-PCR. A total of 67 colorectal tumor RNA (T)
and their corresponding non-tumor RNA (NT) were isolated and
RT-PCR amplified to identify the fusion gene. The RT-PCR amplification
using primers specific for Variant 2 produces 288 bp fragments when
run on 2 % agarose gel. 18 s Ribosomal rRNA was used as
loading control
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2). In addition, Rad51C-ATXN7 fusion DNA was de-
tected in LS-174 T cell and lung tumor genomic DNA
samples by PCR analysis (Additional file 4: Figure S1).
Rad51C-ATXN7 fusion gene expression is associated with
absence of FANCD2 DNA repair foci in colorectal tumors
To assess for functional somatic deficiency in the FA re-
pair pathway, a triple staining immunofluorescence
method (FATSI) was previously developed in our lab to
identify the presence of FANCD2 repair foci in the nu-
cleus of proliferating cells [22]. Based on FATSI, 20 of
67 (30 %) colorectal tumors examined were defective for
FANCD2 foci formation and 47 (70 %) were FANCD2
foci positive (Table 1). We investigated the expression of
Rad51C-ATXN7 fusion gene according to FANCD2 foci
status. Of the 20 FANCD2 foci negative tumors, 12
(60 %) showed expression of the fusion gene. Among the
47 FANCD2 foci positive tumors, 12 (26 %) showed ex-
pression of the fusion gene (Table 1). Thus, the fusion
gene expression is more associated with foci negative tu-
mors (p = 0.012, fisher exact two tailed test).
Rad51C-ATXN7 and microsatellite stability
Microsatellite status was obtained from the surgical path-
ology report based on standard Immuno-histochemistryTable 1 The Rad51C-ATXN7 fusion gene expression in colorectal
tumors
Tumors Tested Fusion Gene Expression
N = 67 N = 24 (36 %)
FANCD2 Foci negative 20 (30 %) 60 % (12/20)
FANCD2 Foci positive 47 (70 %) 26 % (12/47)
Fishers two tailed P Value **0.01
**Indicates significant p value(IHC) analysis evaluating expression of MSH2, MSH6,
MLH1 and PMS2 proteins, in the colorectal tumors [23].
Of the 67 colorectal tumors, we had 54 colorectal tumors
known for microsatellite status, 43 of which were micro-
satellite instable (MSS) and 11 were microsatellite instable
(MSI). Among the 43 MSS tumors, 13 (30 %) tumors
expressed the fusion gene. Of the 11 MSI tumors, fusion
gene was in 6 (55 %) tumors. The fusion gene is more
expressed in the MSI tumors. However, there is no signifi-
cant association statistically between the fusion gene ex-
pression and status of microsatellite (p = 0.166, fisher
exact two tailed test).
Effect of 5-Azacytidine on the expression of Rad51C-
ATXN7 Variants
We have shown several hypermethylated CpG sites within
the promoter of Rad51C [24] and treatment with hypo-
methylating agents causes demethylation at the three
methylated CpG sites in the promoter region. We evalu-
ated if the expression of the Rad51C-ATXN7 fusion gene
could be altered by treatment with DNA hypomethylating
agents. LS-174 T and RKO cells were treated with 5-
Azacytidine at 5 μM for 72 h and the total RNA isolated
from the cells. To quantitatively analyze the effect of pro-
moter methylation on expression of Rad51C-ATXN7 fu-
sion gene, RNA from 5-Azacytidine treated cells as well as
pre-treatment control cells was analyzed with Taqman real
time PCR. The real time PCR primers and respective
amplicon sizes for Variant 2 are described in Additional
file 1: Table S1. 18S ribosomal rRNA was used as en-
dogenous control. The real time PCR analysis showed a
3.51 fold increase in the expression of the fusion gene, re-
spectively, following treatment with 5-Azacytidine as com-
pared to untreated controls (Fig. 4). RKO cells showed 1.2
fold mild increases in the expression of the fusion gene
post treatment. Immunoprecipitation of total Rad51C pro-
tein from the post 5-Azacytdine treated LS-174 T cells
showed higher expression of protein (data not shown) in
comparison to the untreated control.
Translation of fusion transcripts of Rad51C-ATXN7
The Rad51C-ATXN7 fusion transcripts identified from
the colorectal tumors were in silico translated using EM-
BOSS program [25]. The fusion gene (Variant 2) pro-
duced an inframe fusion transcript with predicted
molecular weight of protein 110 KDa (Additional file 2:
Table S2).
To confirm the existence of the fusion protein be-
tween Rad51C and ATXN7, immunoprecipitation of
Rad51C protein was carried out using Dyna MagTM -2
beads from the total cell extracts prepared from the
colon cancer cell lines LS-174 T and RKO. The total
protein was immunoprecipitated using anti Rad51C N-
terminus antibody and the pull down proteins were
Fig. 4 Real time PCR analysis of Rad51C-ATXN7 fusion gene Variant
2 expression in LS-174 T and RKO colorectal tumor cells pre and post
5-Azacytidine treatment. The LS-174 T and RKO cells were treated
with 5-Azacytidine at dose of 5 μM for 72 h. The total RNA was
isolated from pre and post 5-Azacytdine treated LS-174 T and RKO
colorectal tumor cells and reverse transcribed to cDNA. The cDNA
was then used as template for Rad51C-ATXN7 fusion Variant expression
analysis using Taqman real time PCR. The analysis showed 3.51 fold
increase in relative expression of RNA for Variant 2 in comparison to
untreated control in LS-174 T cells. The RKO cells showed only 1.2 fold
mild increase in relative expression of RNA for Variant 2 in comparison
to untreated control
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antibody. As shown in Fig. 5, a protein with molecu-
lar weight of around 110 KDa was observed in the
total and Rad51C antibody immunoprecipitated100 KD
Total        IP        Total      IP  
LS-174T   
120 KD
80 KD
RKO     
1         2    3          4
Fig. 5 Western blot analysis of Rad51C-ATXN7 fusion protein in
colon tumor cells. The immunoprecipitation pull down and immunoblot
detection of the fusion protein Rad51C-ATXN7 in human colon cancer
LS174T and RKO cell lines are shown. The pull down was carried out
using 500 μg total cell lysates prepared from LS-174 T, RKO cells. Briefly,
the total cell lysates were incubated with Dynabeads® containing protein
G and 10 μg mouse monoclonal anti-Rad51C antibody. Immunoblot
detection was carried out using Rabbit polyclonal anti-ATXN7 antibody
and anti-rabbit secondary antibody by loading 150 μg total protein on
4–12 % NuPAGE gel. Lane 1- Total LS174T cell lysate, Lane 2- LS174T
protein immunoprecipitated using anti-Rad51C antibody, Lane 3- Total RKO
cell lysate, Lane 4- RKO protein immunoprecipitated using anti-Rad51C
antibody. The immunoblot was detected using anti-ATXN7 antibodysamples from LS-174 T cells, which was absent in the
RKO cell line.
Differential response to the treatment of cisplatin
between LS-174 T cell and RKO cell
To evaluate the influence of the fusion gene in regarding
to cell viability following exposure to cisplatin, we evalu-
ated survival fractions for the cells that are expressing the
fusion gene (LS-174 T) as compared with non-expressing
cells (RKO) post treatment of cisplatin (5 μg/ml). MTT
assay was used for the cell viability analysis and an aver-
aged absorbance was recorded 24, 48, and 72 h post treat-
ment. MTT data showed that the LS-174 T cells had 60
and 27.5 % of viable cells compared to non-treatment
controls 48 and 72 h post treatment with cisplatin. In con-
trast, there were 80 and 46 % of viable cells in the RKO
population 48 and 72 h post cisplatin treatment (Fig. 6).
These results indicate LS-174 T cells are more sensitive to
the treatment of cisplatin, a DNA interstrand crosslinking
agent.
Discussion
Alterations in several important pathways are involved
in the initiation and progression of colorectal cancers.
These alterations include the common mutations in
APC, TP53, SMAD4, PIK3CA and KRAS genes, and
other less frequent mutations, such as in ARID1A,
SOX9 and FAM123B [26, 27]. By deep sequencing (gen-
omic or RNA sequencing) of colorectal tumors, many
fusion genes have been identified [26, 27]. FurtherFig. 6 MTT assay analysis of cell survival in LS-174 T and RKO cells post
treatment of cisplatin. We analysed cell survival fractions for the cells
that are expressing the fusion gene (LS-174 T) as compared with
non-expressing cells (RKO) post treatment of cisplatin (5 μg/ml). MTT
assay was used for the cell viability analysis and an averaged absorbance
was recorded 24, 48 and 72 h post treatment. Cell viability analysis
showed that the LS-174 T cells had 60 and 27.5 % of viable cells
compared to non-treatment controls 48 h and 72 h post treatment with
cisplatin. In contrast, there were 80 and 46 % of viable cells in the RKO
population 48 h and 72 h post cisplatin treatment. The LS-174 T cell was
more sensitive to the treatment of cisplatin
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identify potential therapeutic targets.
In the current study we evaluated the frequency and
expression of the fusion gene formed between Rad51C
and ATXN7 in colorectal tumors and cell lines. Since
Rad51C is one of the key proteins for the formation of
FA homologous recombination DNA repair foci follow-
ing genotoxic insults, we evaluated if the Rad51C-
ATXN7 fusion protein affected FA repair foci formation.
We had previously shown a splice Variant of the
Rad51C to be overexpressed in colorectal tumors [24].
Here we report the Rad51C-ATXN-7 fusion mRNA
products in the same malignancy. The N-terminus do-
main of Rad51C has DNA dependent ATPase function,
important for homologous recombination mediator ac-
tivity [13, 14]. The fusion transcript Variant 1 could not
produce fusion protein. However, the fusion transcript
Variant 2 is able to form an inframe fusion protein
which contains the N-terminus domain of Rad51C.
Among 67 human colorectal tumors analyzed, there was
a significant correlation between the presence of the fu-
sion gene and lack of FANCD2 foci. Furthermore, we
found that the LS-174 T cells (expressing the fusion
gene) were more sensitive to the treatment of cisplatin
comparing with RKO cells (non-expressing the fusion
gene). These findings taken together may imply a poten-
tial role of the fusion gene in treatment and predictive
value in colorectal cancers. In addition, the fusion gene
is more expressed in the MSI tumors though the associ-
ation between microsatellite stability and expression of
fusion gene was not significant statistically.
Our results also show that the Rad51C-ATXN7 fusion
gene expression was up regulated post treatment of 5-
Azacytdine, a classic demethylation agent. This indicates
that Rad51C promoter methylation can regulate the ex-
pression of fusion gene Variants in colorectal tumors.
We have recently demonstrated several hypermethylated
CpG sites in the promoter of Rad51C which is thought
to regulate Rad51C isoforms [24]. Since expression of
the fusion gene is regulated by treatment of 5-
Azacytidine, the potential role of the fusion protein in
oncogenic function or drug resistance may have clinical
relevance. Functional in vitro and in vivo studies are
needed to evaluate the function of the fusion gene and
to assess the potential prognosis and predictive value of
the Rad51C-ATXN7 fusion gene in colorectal tumors.
Conclusion
In conclusion a chromosomal translocation between
DNA repair gene Rad51C and Ataxin-7 has been identi-
fied in colorectal tumors. The in-frame fusion transcript
results in a fusion protein with molecular weight of 110
KDa. In vitro 5-Azacytidine treatment of colorectal
tumor cells showed expression of the fusion gene isregulated by promoter methylation. Expression of the fu-
sion gene is correlated to FANCD2 foci deficiency in
those colorectal tumors. Further investigation is needed
to elucidate differential function of the Rad51C-ATXN7
fusion gene in colorectal tumors.
Methods
Colorectal patient tumor tissue collection
After Institutional Review Board (IRB) approval, fresh hu-
man tumor and paired non-tumor tissue samples were ob-
tained from tissue procurement at The Ohio State
University, tissues used for RNA and protein analysis were
frozen in liquid nitrogen and stored in a –80 °C freezer.
Tissues used for histological analysis were placed in 10 %
neutral buffered formalin for 12 h, and then stored in PBS.
Total RNA and DNA from the colorectal tumor tissue
samples were isolated by homogenization and sequential
precipitation following the protocol from TRIzol reagent
(Life Technologies). RNA and DNA obtained from the
colorectal tumor tissue samples was quantified at absorb-
ance 260 nm and 280 nm using Nanodrop 2000C
(Thermoscientific).
Primer
The forward and reverse primers were designed using
the Primer3 software [28]. The forward and reverse
primers for the Variant 2 Rad51C-ATXN7 fusion gene
are shown in Additional file 1: Table S1.
cDNA preparation
The total RNA obtained from the colorectal cancer
patients were reverse transcribed to cDNA following
the Superscript™ II Reverse transcriptase protocol
(Invitrogen, CA).
PCR
The optimal temperature was determined for each pair
of primers to be around 60 °C. PCR reactions were per-
formed in 25 μl reaction volume with 1x PCR buffer,
10 mM dNTP mixture, 50 mM MgCl2, 0.2 μM primer of
each forward and reverse, 0.2 μl 1.0 unit Platinum ® Taq
DNA polymerase following the protocol from (Invitrogen,
CA). PCR conditions for each amplicon included 95 °C for
4 min, 95 °C for 30 s, annealing temperature at 60 °C for
30 s and extension at 72 °C for 30 s. Post PCR, the ampli-
cons were analyzed on 1.5 % agarose gel.
RT-PCR
RT-PCR was performed using one step RT-PCR Kit
(Qiagen, CA). The junction specific primers for Variant
2 are SJF, SJR and the sequences are shown in the
Additional file 1: Table S1, along with their respective
amplicon sizes. The RT-PCR was performed in 25 μl re-
action containing final concentration (1x) of 5 μl of 5x
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0.6 μM each of forward and reverse primers, 1 μl of Qia-
gen One step RT-PCR enzyme mix, template RNA up to
2 μg and the volume was made up to 25 μl using PCR
grade water. The PCR was carried out as reverse tran-
scription for 34 min at 52 °C, initial PCR activation for
15 min at 95 °C, 32 cycles of initial denaturation for 30 s
at 95 °C, annealing for 30 s at 60 °C, extension for 30 s
at 72 °C and final extension for 4 min at 72 °C. The
amplified products were gel extracted and purified using
QIAquick Gel Extraction Kit (Qiagen, CA). The purified
products were subjected to direct sequencing using the
primers (Additional file 1: Table S1).
Topo® TA cloning
For rapid and reliable identification of Rad51C-ATXN7
fusion gene, Topo TA cloning was performed following
the protocol from (Invitrogen, CA). The obtained clones
were sent for direct sequencing. To identify the Variant
2, the sequences obtained from TA clones were com-
pared to sequences of Rad51C and ATXN7 mRNA se-
quences in Genbank.
Fanconi anaemia (FA) triple staining immunofluorescence
(FATSI)
The FA triple staining immunofluorescence method has
been previously described [22]. Briefly, FFPE tumor tis-
sue was cut at 4 microns, placed on positively charged
slides, and stained with hematoxylin and eosin. Add-
itional sections for immunofluorescence staining were
placed in a 60 °C oven for one hour, cooled, deparaffi-
nized, and rehydrated through xylenes and graded etha-
nol solutions to water in standard fashion. Antigen
retrieval was performed by placing slides in Dako’s TRS
antigen retrieval solution (Dako) in a calibrated vege-
table steamer (Black and Decker) at 94 °C for 25 min.
Slides then were placed on a Dako Autostainer for auto-
mated staining. The tissue sections were incubated with
a primary antibody cocktail of rabbit polyclonal FANC-
D2 antibody at a dilution of 1:1,000 and a monoclonal
anti-Ki67 mouse antibody (Dako) at a dilution of 1:150,
for one hour at room temperature. Sections then were
incubated with a secondary antibody (FITC conjugated
to anti-rabbit IgG and Alexa fluor 594 donkey anti-
mouse IgG, Invitrogen) at 1:1,000 for one hour at room
temperature. The sections were mounted on glass slides
using a 4′ 6-diamidino-2-phenylindole (DAPI)-contain-
ing embedding medium (Vysis Dapi 1, Abbott Labora-
tories). The slides were analyzed under a Nikon E-400
fluorescence microscope [22].
5-Azacytidine (5-Aza) treatment of cells
Human colon cancer cell lines LS-174 T and RKO were
purchased from ATCC® and were grown in completeEagle’s Minimum Essential Medium with 10 % fetal bo-
vine serum and 1 % penicillin/streptomycin at 37 °C
(5 %, CO2). For the treatment of cells, 5-Azacytidine was
filter-sterilized and added directly to the fresh cell culture
media. Fresh 5-Azacytidine was added every 24 h at dose
of 5 μM for 72 h. The post treatment cells were lysed, and
the pellets were collected and stored at −80 °C.
Real time PCR
The RNA expression levels of the target fusion gene
were analyzed by Taqman real time PCR. The RNA was
isolated from the 5-Azacytidine treated cells and reverse
transcribed to cDNA using Superscript™ II Reverse Tran-
scriptase from Invitrogen (CA, USA).
The primers for real time PCR amplification were de-
signed using Primer3 software. The TaqMan MGB FAM
labelled probes were purchased from Applied Biosystems
(Foster City, CA). The 6-FAM labelled probes and the
primers used for real time PCR amplification for Variant
2 are listed in Additional file 1: Table S1, along with
respective amplicon sizes. The cDNA was used as tem-
plate and the final reaction consisted of 1x Taqman® Fast
Advanced Master Mix (Applied Biosystems, Carlsbad,
CA), 3.0 μM FAM labelled probe, 10pmol/μl of forward
and reverse primers, Human 18S rRNA VIC-MGB in-
ternal control, Applied Biosystems (Foster City, CA).
Immunoprecipitation
Human colon cancer cell lines LS-174 T and RKO were
grown in EMEM medium with 10 % fetal bovine serum
and penicillin/streptomycin at 37 °C (5 %CO2). The cells
were lysed in lysis buffer containing 1 mM PMSF,
0.5 mM DTT and 1 mM cocktail. The total cell lysates
containing equal amounts of protein (500 μg) were
immunoprecipitated using magnetic beads coupled pro-
tein G following Dynabeads® protocol (novex®, Life tech-
nologies). Briefly, total cell lysates were pre-incubated
with mouse monoclonal Rad51C antibody (Santa Cruz
Biotechnology, CA) overnight at 4 °C while rotating,
washed and eluted the IP product in 20 μl volume using
elution buffer by the supplier (novex®, Life technologies)
and stored at −80 °C for detection using immunoblot.
Immunoblot
Equal amount of proteins isolated from cells and tumor
tissues were size fractionated on 4–12 % NuPAGE gel.
Proteins were then transferred onto nitrocellulose mem-
brane. The membrane was blocked with blocking buffer
(5 % non fat milk). The blocked membrane was then in-
cubated with target antibody rabbit polyclonal ATXN7
antibody (Bethyl Laboratories INC, TX) at 4 °C over-
night. After washing the membrane with TBS-T (20 mM
Tris, 0.9 % Nacl) for three times 20 min each, the mem-
brane was then incubated with anti-rabbit secondary
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temperature. The detection of specific protein binding
was performed with a chemiluminescence kit (Amersham,
GE Healthcare, UK).
MTT
Five thousand cells from each line were seeded in each
well of a 96-well plate 24 h before treatment. Cells were
treated with cisplatin (5 μg/ml). Dimethylthiazolyl-2-
5-diphenyltetrazolium bromide (MTT) dye solution (Sigma,
St. Louis, MO) was added into the 96-well plate. The plate
was incubated at 37 °C for 4 h, and then the treatment was
terminated by adding stop solution (isopropanol with
0.04 N HCl). MTT was cleaved by live cells to a colored
formazan product. Absorbance at 560 nm wavelength was
recorded using a Bio-Rad microplate reader 680 (Bio-Rad
Laboratories, Hercules, CA). Each treatment was re-
peated in triplicate. An averaged absorbance of blank
values (containing all reagents except cells) was subtracted
from all absorbance to yield corrected absorbance. The
relative absorbance of each sample was calculated by com-
paring the average of corrected absorbance with an aver-
age of corrected untreated control.
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Additional file 1: Table S1. Primer sequences and amplicon sizes.
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Additional file 2: Table S2. In silico translation of fusion gene Rad51C-
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Additional file 3: Table S3. Sybr green qPCR analysis of all 24 fusion
positive tumor pairs (tumors and non-tumors). Following are the CT
values for tumors (Label T1-T24), matched non-tumors (NT1-NT24) and
non-template controls (C-T–). (DOCX 33 kb)
Additional file 4: Figure S1. PCR amplification of Rad51C-ATXN7 fusion
DNA: Genomic DNA was isolated from the LS 174 T, MCF-7, RKO, tumors
(T) and non-tumors (NT). PCR was and performed using forward primer
(sequence 5′-GCCCTGGGTTTTAAGGT TTT-3′) located in the intron 5 of
Rad51C and reverse primer (5′ATGCATTGGCCTGGTGTT-3′) located in
exon-6 of ATXN7. The expected PCR product was amplified mainly in the
LS-174 T cell, human colorectal tumor (T). (PDF 91 kb)
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